Jan Vijg

Jan Vijg chairs the Department of Genetics at Albert Einstein College of Medicine, where he holds the Lola and Saul Kramer Chair in Molecular Genetics [1]. His research centers on genome instability, the idea that mutations and other forms of DNA damage accumulate in the genomes of individual somatic cells throughout life, eventually driving tissue dysfunction and disease characteristic of aging [2].

In a widely cited 2013 review published in the Annual Review of Physiology, Vijg and co-author Yousin Suh laid out the somatic mutation theory of aging in detail, arguing that unlike the germline, which is protected by robust DNA repair and quality-control mechanisms, somatic cells accumulate mutations, structural variants, and epigenetic changes over a lifetime in a way that is inherently stochastic and cell-to-cell variable [2]. This variability is itself a key claim of the theory: two genetically identical cells in the same tissue can end up with very different mutation burdens purely by chance, which the theory uses to explain why aging phenotypes are heterogeneous even among genetically similar individuals [2].

Vijg's lab pioneered single-cell sequencing methods specifically to measure somatic mutation burden directly in individual cells rather than relying on bulk-tissue averages, which can mask the true extent of cell-to-cell variation [2]. This technical capability became commercially valuable, and Vijg co-founded SingulOmics Corp. and MutagenTech Inc. to develop and sell single-cell genomic sequencing services and tools built on techniques originating in his academic lab [3]. A 2024 paper on which Vijg is a co-author discloses this relationship directly, stating a competing financial interest tied to his role at these companies [3].

This dual role, academic originator of a mutation-detection method and co-founder of companies selling services built on that same method, is a standard and disclosed form of academic technology transfer rather than a hidden conflict; Vijg's papers using the single-cell sequencing approach consistently carry the competing-interest disclosure [3]. It does mean that Vijg has a direct financial interest in the continued scientific and commercial relevance of single-cell somatic mutation sequencing as a field, which is worth naming even though disclosure practices here meet the normal academic standard.

On the broader question of whether somatic mutation accumulation is a primary cause of aging, as opposed to one contributing factor among several (epigenetic drift, proteostasis collapse, mitochondrial dysfunction, and others featured throughout this wiki), Vijg has argued for its centrality but the field has not settled on a single dominant causal mechanism, and Vijg's own writing generally frames somatic mutation as one of several interacting hallmarks rather than a sole cause [2]. His empirical contribution, demonstrating that single-cell mutation burden is measurable and does increase with age and vary by tissue, is on firmer ground than any claim about its relative causal weight compared to other aging mechanisms.

The plain takeaway: Vijg built genuinely useful single-cell sequencing tools that let researchers measure something previously invisible, cell-by-cell mutation accumulation, and that measurement capability is now sold commercially through companies he co-founded, a standard technology-transfer arrangement; whether somatic mutation accumulation deserves the primary causal role Vijg's framing gives it, versus being one of several contributing mechanisms, remains an open scientific question rather than a settled result.